Boston-based Bicara launched in 2021, and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo ...

A researcher with The University of Texas Health Science Center at San Antonio School of Dentistry and her biotechnology company teamed with the school to earn a $400,000 Small Business Technology ...

Oral squamous cell cancer, or OSCC, arises in the cells that line the mouth. The disease is often diagnosed at a late stage, ...